Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
暂无分享,去创建一个
Jacques P. Brown | D. Felsenberg | J. Kaufman | I. Reid | S. Ortolani | M. Brandi | J. Body | A. Genazzani | M. Hooper | J. Devogelaer | P. Meunier | G. Leb | H. Mallmin | J. Ittner | P. Burckhardt | A. Rubinacci | G. Samsioe | P. Jaeger | U. Trechsel | L. Verbruggen | T. Murray | Z. Horowitz | M. Saaf | P. Richardson | A. Widmer | J. Broell | R. Di Micco | J. Happ
[1] P Geusens,et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.
[2] G. Mills,et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Ingle,et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. , 2000, Cancer research.
[4] M. Andersen,et al. Compliance to bisphosphonates - a population-based study using a drug prescription database , 2000 .
[5] P. Roberson,et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. , 1999, The Journal of clinical investigation.
[6] H K Genant,et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.
[7] G. Romieu,et al. A Dose‐Finding Study of Zoledronate in Hypercalcemic Cancer Patients , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[8] D. Hutchins,et al. Patient Noncompliance with Hormone Replacement Therapy: A Nationwide Estimate Using a Large Prescription Claims Database , 1998, Menopause.
[9] J. Kanis,et al. Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] D. Thiebaud,et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. , 1997, The American journal of medicine.
[11] S L Hui,et al. Universal Standardization of Bone Density Measurements: A Method with Optimal Properties for Calibration Among Several Instruments , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] M. Urist,et al. Bone Morphogenetic Protein: The Molecularization of Skeletal System Development , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[13] S. Cummings,et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.
[14] C. Christiansen,et al. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study , 1996 .
[15] G. Rodan,et al. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. , 1996, Bone.
[16] P. Geusens,et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. , 1996, Bone.
[17] J Dequeker,et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.
[18] H. Genant,et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. , 1995, The American journal of medicine.
[19] P. Delmas,et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. , 1994, The Journal of clinical endocrinology and metabolism.
[20] I. Reid,et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. , 1994, The Journal of clinical endocrinology and metabolism.
[21] G. Rodan,et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. , 1991, The Journal of clinical investigation.
[22] M. Passeri,et al. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. , 1991, Bone and mineral.
[23] W. Mysiw,et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[24] H. Genant,et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.
[25] K. Gabriel,et al. On closed testing procedures with special reference to ordered analysis of variance , 1976 .